Lapatinib is frequently used in combination with other therapeutic agents for treating high-risk metastatic breast cancer patients, particularly in cases where they display resistance to trastuzumab, a first-line therapeutic agent for HER2-positive breast cancer [3, 4]. Here, ERBB2 is linked to breast cancer.